Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment (DICO)

Karolinska Institute

Status: Completed

Conditions: Human Immunodeficiency Virus; Chronic Hepatitis C

Treatments: Drug: pegylated interferon-alpha (Pegasys); Drug: ribavirin (COPEGUS)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00909129

03-541

Details and patient eligibility

About

The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response. Furthermore, to study Interferon-inducible protein-10 (IP-10) dynamics during HCV treatment, and correlate this to treatment outcome.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-1 Hepatitis C coinfected adult patients
• Hepatitis C treatment naive
• Stable HIV-1 infection with or without cART
• > 300 CD4+ cell count

Exclusion criteria

• Decompensated liver disease
• Ongoing depression
• Ongoing drug abuse
• Other contraindications for interferon or ribavirin treatment

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

HIV-1 HCV coinfected patients

Experimental group

Description:

HIV-1 HCV coinfected patients undergoing HCV therapy

Treatment:

Drug: ribavirin (COPEGUS)

Drug: pegylated interferon-alpha (Pegasys)